The pharmacokinetics of combination therapy with nelfinavir plus nevirapine

AIDS

Volumn 12, Issue 10, 1998, Pages 1163-1167

  Merry, Concepta ^a,b   Barry, Michael G ^a   Mulcahy, Fiona ^b   Ryan, Mairin ^b   Tjia, John F ^a   Halifax, Kathryn L ^a   Breckenridge, Alasdair M ^a   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Nelfinavir; Nevirapine; Pharmacokinetic interaction

Indexed keywords

NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; SALVAGE THERAPY;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0032500016     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199810000-00008     Document Type: Article

References (23)

1. De Cock KM: Guidelines for managing HIV infection. BMJ 1997, 315:1-2.
2. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
3. Hogg RS, O'Shaughnessy MV, Gataric N, et al.: Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997, 349:1294.
4. Torres RA, Barr M: Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997, 336:1531-1532.
5. Mouton Y, Alfandari S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-F105.
6. Fätkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
7. de Truchis P, Force G, Zucman D, et al.: Effects of a salvage combination therapy with ritonavir and saquinavir in HIV infected patients previously treated with protease inhibitors. VI European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 376].
8. Perry CM, Benfield P: Nelfinavir. Drugs 1997, 54:81-87.
9. Merry C, Barry MG, Mulcahy F, Halifax KL, Back DJ: Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997, 11:F117-F120.
10. Murphy RL, Montaner J: Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996, 5:1183-1199.
11. Gagnier P, Myers M, Lamson M, Greguski R, Love J, Chodakewitz J: Effect of nevirapine (NVP) on pharmacokinetics (PK) of indinavir (IDV) in HIV-1 patients, fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 554].
12. Spence RA, Anderson KS, Johnson KA: HIV-1 reverse transcriptase resistance to non nucleoside inhibitors. Biochemistry 1996, 35:1054-1063.
13. Havlir D, Cheeseman SH, McLaughlin M, et al.: High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.
14. de Jong MD, Vella S, Boucher CAB, et al.: High dose nevirapine in previously untreated human immunodeficiency virus type 1 infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997, 175:966-970.
15. Sahai J, Cameron W, Salgo M, et al.: Drug interaction study between saquinavir (SQV) and nevirapine (NVP). Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 614].
16. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
17. Barry M, Gibbons S, Back D, Mulcahy F: Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997, 32:194-209.
18. Lamson M, Gagnier P, Greguski R, Myers M, Leonard J: Effect of nevirapine (NVP) on pharmacokinetics (PK) of ritonavir (RTV) in HIV-1 patients. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 556].
19. Dusek A, Myers M, Gagnier P, et al.: Long term activity of nevirapine combined with indinavir in HIV infected adults. VI European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 106].
20. Ferry JJ, Schneck DW, Carlson GF, et al.: Evaluation of the pharmacokinetic (PK) interaction between ritonavir (R) and delavirdine (DLV) in healthy volunteers. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 121].
21. Morse GD, Shelton MJ, Hewitt RG, et al.: Ritonavir (RIT) pharmacokinetics (PK) during combination therapy with delavirdine. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 343].
22. D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996, 124:1019-1030.
23. Skowron G, Leoung G, Dusek A, et al.: Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): preliminary safety, activity and pharmacokinetic (PK) interactions. Fifth Conference on AIDS 1998, 12:1169-1176